美年大健康产业控股股份有限公司 证券代码：002044 证券简称：美年健康 公告编号：2025-029 特此公告。 美年大健康产业控股股份有限公司 监 事 会 二〇二五年五月十日 关于监事会延期换届的提示性公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 美年大健康产业控股股份有限公司（以下简称"公司"）第八届监事会任期将 于 2025 年 5 月 16 日届满。鉴于新修订的《中华人民共和国公司法》（以下简称 "公司法"）、《上市公司章程指引》及《关于新<公司法>配套制度规则实施相关 过渡期安排》等要求，以及公司换届工作尚在筹备中，为确保公司相关工作的连 续性和稳定性，公司第八届监事会的换届选举工作将适当延期。 在换届工作完成前，公司第八届监事会全体成员将依照相关法律法规以及 《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》《公司章程》等有关规定继续履行监事的职责和 义务。本次监事会延期换届不会影响公司的正常运营，公司将尽快推进相关工作， 并及时履行相应的信息披露义务。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 美年大健康产业控股股份有限公司（以下简称"公司"）2024 年度股东大会现 场会议的召开地点为上海市静安区灵石路 697 号健康智谷 9 号楼三楼公司会议 室，敬请投资者特别留意。 根据公司于 2025 年 4 月 15 日召开的第九届董事会第八次会议，定于 2025 年 5 月 14 日召开公司 2024 年度股东大会，本次股东大会将采用股东现场记名投 票与网络投票表决相结合的方式召开，《关于召开 2024 年度股东大会的通知》 （公告编号：2025-021）已于 2025 年 4 月 17 日披露在《中国证券报》、《上海 证券报》、《证券时报》、《证券日报》和巨潮资讯网（www.cninfo.com.cn）。 现就本次股东大会的有关事宜发布提示性公告如下： 证券代码：002044 证券简称：美年健康 公告编号：2025-028 美年大健康产业控股股份有限公司 关于召开 2024 年度股东大会的提示性公告 （2）网络投票时间：2025 年 5 月 14 日（星期三）9:15-15:00。 1 1）通 ...

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a recent increase, reflecting a mixed performance over different time frames [1][2]. Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services rose by 0.39% to 13,367.74 points, with a trading volume of 14.635 billion yuan [1]. - Over the past month, the index has increased by 5.82%, while it has decreased by 2.05% over the last three months and by 2.72% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, selected from the broader China Securities Index to reflect the overall performance of healthcare-related securities [1]. - The top ten weighted companies in the index include: Mindray Medical (9.57%), Aier Eye Hospital (8.34%), United Imaging (7.63%), Aimeike (3.55%), Huatai Medical (3.28%), Yuyue Medical (2.88%), New Industry (2.81%), Meinian Onehealth (2.35%), Lepu Medical (2.07%), and Jiuan Medical (2.03%) [1]. Group 3: Market Segmentation - The index's holdings are primarily listed on the Shenzhen Stock Exchange (60.66%) and the Shanghai Stock Exchange (39.34%) [1]. - In terms of industry composition, medical devices account for 34.34%, medical consumables for 27.26%, in vitro diagnostics for 21.50%, and medical services for 16.90% [2]. Group 4: Fund Tracking - Several public funds track the China Securities Index for Healthcare Equipment and Services, including Southern China Securities Index Healthcare Equipment and Services Link A, C, and I, Tianhong China Securities Index Healthcare Equipment and Services ETF, and others [2].

Core Insights - The release of the "Ciming Beijing 2024 Annual Health Checkup Big Data Blue Book" aims to provide dynamic observation for public health research and optimize disease screening paths for medical institutions [1][2] - Ciming Health has introduced three innovative health management products that integrate smart technology and customized service systems to enhance public health literacy [1][2] Group 1: Blue Book Overview - The data for the Blue Book is sourced from health checkup data of 1.1346 million individuals from 19 health checkup centers in Beijing, focusing on common diseases in six major health areas [2] - The analysis targets the "post-70s," "post-80s," and "post-90s" demographics, with an average age of 43, comprising 51.9% males and 48.1% females [2] Group 2: Product Innovations - The three innovative health management products include weight management, blood sugar management, and the upgraded "Magnetic Capsule Gastroscope System" robot [1][14] - The weight management product offers a comprehensive approach with eight service items, including lifestyle assessments and personalized weight loss plans [14][15] - The blood sugar management product targets high-risk groups and provides a series of services to help manage and reverse diabetes effectively [14][15] Group 3: Industry Impact and Future Directions - Ciming Health is recognized for its contributions to health management and is seen as a pioneer in integrating smart medical innovations and health big data applications [7][9] - The company aims to leverage technology and innovation to drive high-quality development and establish itself as a leading brand in health checkups and management in the capital region [12][18] - Future initiatives will focus on cancer early screening, chronic disease management, and mental health, with a commitment to integrating digital operations and AI technologies [18]

Group 1 - The core viewpoint of the news is that a comprehensive financial policy package has been introduced to support the stability of the market and expectations, particularly benefiting the elderly care sector [1][3] - The People's Bank of China has established a 500 billion yuan service consumption and elderly care relending tool to enhance financial support for key areas such as elderly care and service consumption [3] - The elderly care industry in China is projected to reach a scale of 9 trillion yuan in 2022, with expectations to exceed 12 trillion yuan by 2025, indicating a significant growth phase ahead [4][5] Group 2 - The elderly care concept stocks have shown strong performance, with multiple stocks such as Jinming Precision Machinery and Xinhua Jin experiencing significant price increases, some reaching the daily limit [2] - The new policy tool is an expansion and upgrade of the previous inclusive elderly care relending policy, which had a smaller quota of 40 billion yuan and was initially piloted [3] - The silver economy is expected to grow substantially, with projections indicating it could reach 30 trillion yuan by 2035, accounting for 10% of GDP, driven by various sectors including elderly services and health care [4]

最新一期业绩显示，2025年一季报，公司实现营业收入17.54亿元，同比-2.62%；净利润-275338119.16 元，同比3.94%，销售毛利率24.04%。 5月6日，美年健康今日收盘5.45元，上涨2.06%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到72.68倍，创13天以来新低，总市值213.33亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均38.66倍，行业中值38.36倍，美年健康排 名第37位。 截至2025年一季报，共有50家机构持仓美年健康，其中基金42家、其他8家，合计持股数166292.92万 股，持股市值93.79亿元。 美年大健康产业控股股份有限公司的主营业务是健康体检服务。公司的主要产品是体检服务。 序号股票简称PE(TTM)PE(静)市净率总市值(元)37美年健康72.6875.582.80213.33亿行业平均 38.6644.753.42152.65亿行业中值38.3646.642.7251.49亿1润达医疗-313.36207.372.70114.63亿2何氏眼 科-135.21-117.661.6932.24亿3*ST生物-102. ...

Group 1 - Kexin Technology plans to repurchase shares worth between 30 million and 50 million yuan, with a maximum repurchase price of 80 yuan per share, for employee stock ownership plans or capital reduction [1] - Jiahua Technology's shareholder plans to reduce holdings by up to 1.5% of the company's total shares, amounting to a maximum of 116,000 shares, between May 28, 2025, and August 25, 2025 [1] - Beiqi Blue Valley's subsidiary reported cumulative sales of 38,041 vehicles this year, representing a year-on-year increase of 192.53% [2] Group 2 - AVIC Finance plans to transfer shares of AVIC Xi'an Aircraft Industry Group and AVIC Onboard Systems, totaling 4.067 billion yuan, to its controlling shareholder [2] - Haide shares' executives plan to increase their holdings by at least 20.73 million yuan within six months [3] - Dabeinong's subsidiary received planting approval for genetically modified soybeans in Brazil, marking significant progress in the South American market [4] Group 3 - Yongan Pharmaceutical's chairman is under investigation, but the company's operations remain normal [4] - Teruid's subsidiary is expected to win a 126 million yuan project from the State Grid, which will enhance the company's brand and industry influence [4][5] - Junxin shares plan to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 30.57 yuan per share [5] Group 4 - Meinian Health plans to reduce its holdings by up to 3% of the company's total shares, amounting to a maximum of 11.7 million shares, starting from May 27, 2025 [7] - Electric Power Investment is planning a major asset restructuring, leading to a temporary suspension of its stock [9] - Tongda shares are expected to win a 207 million yuan project from the State Grid, which will positively impact future operating performance [10] Group 5 - Xintian Technology's major shareholder plans to reduce holdings by up to 3% of the company's total shares, amounting to a maximum of 580,410 shares [11] - Huizhou Intelligent's controlling shareholder and some executives plan to increase their holdings by between 29.2 million and 58.4 million yuan [12] - Zhongdali De plans to sell a 50% stake in Shanghai Ketaike Transmission System Co., Ltd. for 9.2777 million yuan to optimize its asset structure [14] Group 6 - Jinlitai's stock will be suspended due to the inability to disclose periodic reports within the statutory deadline [15] - Chuhuan Technology's major shareholder plans to reduce holdings by up to 3% of the company's total shares, amounting to a maximum of 239,560 shares [15] - Guilin Sanjin's subsidiary received approval for clinical trials of a new indication for a monoclonal antibody injection [16] Group 7 - Plit plans to sign a strategic supply agreement for sodium-ion batteries, committing to supply at least 1 GWh over four years [17] - Dalian Electric Porcelain's subsidiary is expected to win a project worth approximately 71 million yuan from the State Grid [18]

Group 1 - Major shareholders of *ST WanFang plan to reduce their holdings by up to 9,341,596 shares, accounting for 3% of the company's total share capital from May 27 to August 25, 2025 [1] - Shareholders of Airo Energy intend to reduce their holdings by up to 800,000 shares, 800,000 shares, and 1,600,000 shares, representing 0.50%, 0.50%, and 1% of the company's total share capital respectively during the same period [1] - Anner plans to reduce its holdings by up to 3,186,159 shares, which is 1.5% of the company's total share capital, from May 27 to August 26, 2025 [1] Group 2 - Shareholders of Chuhuan Technology plan to reduce their holdings by up to 2,395,605 shares, accounting for 3% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [1] - Major shareholder of Dalian Technology intends to reduce their holdings by up to 4,189,336 shares, which is 0.99% of the company's total share capital from May 27 to August 26, 2025 [2] - Dongwei Technology's board members plan to reduce their holdings by a total of 2,574,857 shares, representing 0.8629% of the company's total share capital during the same period [2] Group 3 - Gann Li Pharmaceutical's shareholder has completed a reduction of 6,010,622 shares, which is 1% of the company's total share capital from April 22 to April 30, 2025 [2] - Guanshi Technology's board members plan to reduce their holdings by up to 359,375 shares, accounting for 0.4891% of the company's total share capital from May 27 to August 26, 2025 [2] - Guoguang Electric's shareholder has completed a reduction of 1,625,751 shares, which is 1.5% of the company's total share capital from April 25 to April 30, 2025 [2] Group 4 - Haili Biological's major shareholder has completed a reduction of 13,113,244 shares, representing 2% of the company's total share capital from April 15 to April 22, 2025 [3] - Hengfeng Information's board member has completed a reduction of 198,717 shares, which is 0.1207% of the company's total share capital on April 28, 2025 [3] - Hongwei Technology's shareholder plans to reduce their holdings by up to 820,000 shares, accounting for 0.39% of the company's total share capital from May 12 to August 11, 2025 [3] Group 5 - Huatai Medical's vice president has completed a reduction of 29,943 shares, which is 0.0308% of the company's total share capital from April 28 to April 29, 2025 [4] - Jilin Carbon Valley's major shareholder has completed a reduction of 4,989,160 shares, representing 0.8490% of the company's total share capital from April 25 to April 29, 2025 [4] - Jiahua Technology's shareholder plans to reduce their holdings by up to 1,160,000 shares, accounting for 1.50% of the company's total share capital from May 28 to August 25, 2025 [4] Group 6 - Jiangbo Long's shareholder plans to reduce their holdings by up to 4,159,815 shares, which is 1% of the company's total share capital from May 27 to August 26, 2025 [5] - Jiangshan Co. plans to reduce its holdings in Jiangtian Chemical by 4,330,800 shares, accounting for 3% of its total share capital from May 27 to August 26, 2025 [5] - Kairun Co.'s major shareholder plans to reduce their holdings by up to 9,000,000 shares, representing 2.43% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [5] Group 7 - Lianqi Technology's shareholders plan to reduce their holdings by a total of 18,717,374 shares, which is 2.96% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [9] - Zhongke Information's board members have completed a reduction of 698,914 shares, representing 0.2358% of the company's total share capital [9] - Zhongshi Co.'s major shareholder plans to reduce their holdings by up to 1,800,000 shares, accounting for 1.1527% of the company's total share capital from May 27 to August 26, 2025 [10]

公司股东杭州信投信息技术有限公司保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、截至本公告披露日，杭州信投信息技术有限公司（以下简称"杭州信投"） 持有美年大健康产业控股股份有限公司（以下简称"公司"、"本公司"）195,996,049 股股份（占公司总股本比例 5.01%），杭州信投及其一致行动人杭州灏月企业管 理有限公司合计持有公司 509,933,846 股股份（占公司总股本比例 13.03%）。 美年大健康产业控股股份有限公司 关于 5%以上股东减持股份的预披露公告 2、杭州信投因自身资金需求，拟在减持预披露公告发布之日起 15 个交易日 后的三个月内，以集中竞价及/或大宗交易方式减持公司股份不超过 117,427,617 股，即不超过公司总股本的 3%。其中，通过集中竞价交易方式减持的股份不超 过 39,142,539 股，即不超过公司总股本的 1%；通过大宗交易方式减持的公司股 份不超过 78,285,078 股，即不超过公司总股本的 2%。 公司于近日收到 5%以上股东杭州信投 ...

Core Viewpoint - Meinian Health has reported strong growth in its AI-driven healthcare services, with Q1 2025 revenue reaching 1.754 billion yuan, including over 54 million yuan from AI technology, marking a 71.76% increase year-on-year, indicating a significant shift from technological exploration to large-scale application in the "AI + healthcare" model [1] Group 1: AI Empowerment in Health Management - Meinian Health's core strategy revolves around "AI + healthcare," transforming the entire health check process into an intelligent service system, covering pre-examination, examination, and post-examination stages [1] - In the pre-examination phase, AI technology customizes health check packages based on individual and group client data, ensuring precision and relevance in health assessments [2] - During the examination, the company has implemented intelligent management tools that enhance customer experience and facilitate seamless transitions from routine screenings to precise diagnostics [2] - Post-examination services leverage AI systems like "Health Xiaomei" to provide personalized health management, with significant improvements in report accuracy and processing efficiency [2] Group 2: Innovation and Competitive Advantage - Meinian Health focuses on building eight core disciplines, utilizing AI to create unique competitive barriers, particularly in ultrasound technology [3] - The company has introduced specialized AI products for various health management areas, enhancing screening efficiency and promoting systematic solutions for early detection [4] - Innovative screening models, such as the "CT One Scan Multiple Checks" system, integrate multiple assessments into a single examination, significantly improving efficiency [4] Group 3: Expansion of Post-Examination Market - The company is transitioning from traditional health check services to comprehensive lifecycle health management, activating deeper individual client needs through innovative operational strategies [5] - Meinian Health is enhancing customer engagement by providing a one-stop solution that includes health checks, specialized examinations, health management, and insurance [6] Group 4: Industry Impact and Future Outlook - Meinian Health is evolving from a health check service provider to an AI health management solution platform, establishing a dual engine for performance growth through specialized early screening products and intelligent health management [7] - The company aims to leverage AI technology to expand into trillion-level markets, focusing on senior health, health management, and data elements, positioning itself as a leader in the digital health management era [8]